Shirley Chen
Stock Analyst at Barclays
(2.96)
# 2,649
Out of 4,574 analysts
36
Total ratings
61.5%
Success rate
6.1%
Average return
Main Sectors:
Stocks Rated by Shirley Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMS: LKFT Lakefront Biotherapeutics NV | Maintained: Sell | €22.00 | €24.50 | -10.20% | 4 | May 7, 2026 | |
| STO: SOBI Swedish Orphan Biovitrum AB (publ) | Maintained: Buy | kr 350.00 → kr 470.00 | kr 457.40 | +2.75% | 5 | Feb 24, 2026 | |
| EPA: SAN Sanofi | Maintained: Buy | €105.00 | €76.03 | +38.10% | 1 | Dec 15, 2025 | |
| SWX: NOVN Novartis AG | Maintained: Sell | CHF 90.00 | CHF 126.90 | -29.08% | 6 | Nov 21, 2025 | |
| LON: 0MGB Genmab A/S | Maintained: Buy | kr 1,875 → kr 2,000 | kr 1,877 | +6.53% | 9 | Nov 10, 2025 | |
| LON: GSK GSK plc | Maintained: Hold | 1,450p | 1,920p | -24.46% | 6 | Oct 31, 2025 | |
| LON: AZN AstraZeneca PLC | Maintained: Buy | 14,000p | 12,670p | +10.50% | 5 | Oct 21, 2025 |
Lakefront Biotherapeutics NV
May 7, 2026
Maintained: Sell
Price Target: €22.00
Current: €24.50
Upside: -10.20%
Swedish Orphan Biovitrum AB (publ)
Feb 24, 2026
Maintained: Buy
Price Target: kr 350.00 → kr 470.00
Current: kr 457.40
Upside: +2.75%
Sanofi
Dec 15, 2025
Maintained: Buy
Price Target: €105.00
Current: €76.03
Upside: +38.10%
Novartis AG
Nov 21, 2025
Maintained: Sell
Price Target: CHF 90.00
Current: CHF 126.90
Upside: -29.08%
Genmab A/S
Nov 10, 2025
Maintained: Buy
Price Target: kr 1,875 → kr 2,000
Current: kr 1,877
Upside: +6.53%
GSK plc
Oct 31, 2025
Maintained: Hold
Price Target: 1,450p
Current: 1,920p
Upside: -24.46%
AstraZeneca PLC
Oct 21, 2025
Maintained: Buy
Price Target: 14,000p
Current: 12,670p
Upside: +10.50%